Video
Author(s):
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.